*Corresponding author:
Miklos Udvardy, Professor Emeritus, Debrecen Medical University, Faculty of Medicine, Department of Hematology,4032 Debrecen, Nagyerdei krt 98, HungaryReceived: June 06, 2018; Published: June 19, 2018
DOI: 10.26717/BJSTR.2018.05.001252
To view the Full Article Peer-reviewed Article PDF
Preparative and clinical transfusiology and transfusion, a majestic part of clinical medicine saved and saves the life of hundred millions. However, times and pathogens are continously and rather quickly changig, so during the last decade many not only egzotic new or newly recognised pathogens and diseases were showed up, and some of them (e.g. Zyka virus, Hepatitis E vrus, Ebola, etc.) can also be transmitted by blood or blood component transfusions, and in some instances they escape from standard screening and inactivation procedures. Hereby we try to focus and draw attention to some of these potentially pathogen new bloodborne microbiological agents, and along with this we try to emphasize the significance of application of updated next generation screenig and inactivation procedures. Interestingly a recent British trial, based on large population data showed some evidence of slight increase of non Hodgkin lymphoma incidence in patients with multiple previous transfusions.
Our approach is purely a clinician one (clinical hematologist), bedside oriented. These new facts, knowledge and skills are badly needed for all of us: doctors (a broad, almost entire range of specialists), blood banking people, departments of epidemiology and also some special cohorts of patients: i.e. for the hemophiliacs and their family, who still receive plasma derived prophylactic treatment 3 times weekly. It is due time, that some especially endangered cohorts of patients and family should receive the necessary information, and go for a fully informed consent based preference, based on the advantages and hazards of particular treatment modalities.
Keywords: Newly Recognised Bloodborne Pathogens; Screening and Inactivation; Refreshing Transfusion Transmitted Clinical Settings; Haemodialysis; Cryoprecipitate; Propionibacterium, Staphylococcus, Bacillus Enterococcus; Ixodus Scapularis; Ribavirin Treatment
Abbrevations: AIDS: Acquired Immundeficiency Syndrome; CMV: Cytomegalo Virus; ELISA: Enzymatic Immunoassay; FDA: Federal Drug Administration, US; EASL: European Association Of Liver Diseases; HIV: Human Immunodeficiency Virus; HEV: Hepatitis E Virus; NAT: Nucleic Acid Based Test; PCR: Polymerase Chain Reaction ; TTP/HUS:Thrombotic Thrombocytopenic Purpura/Haemolytic Uraemic Syndrome; TT virus. (torque teno): Transfusion Transmitted Virus Species; USUV: APathogen Resembling West-Nile Virus
Abstract| Introduction| Discussion and Recommendations| References|